Fosun Pharma (600196.SH): Ibuprofen patch approved for clinical trials.

Wisdom Financial News App, Fosun Pharma (600196.SH) issued an announcement recently that its controlling subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd. (hereinafter referred to as "Chaohui Pharmaceutical"), has received approval from the National Medical Products Administration (hereinafter referred to as "NMPA") to conduct clinical trials for ketoprofen patch (hereinafter referred to as "the drug"). Chaohui Pharmaceutical plans to conduct Phase III clinical trials of the drug in China once the conditions are met.